HOME >> BIOLOGY >> NEWS
Stanford researchers create diabetic fruit flies in lab

nearly identical in flies and humans, including the genes and molecular defenses used by the two systems. Because of this similarity, researchers have been able to learn more about the human immune system by studying flies.

Rulifson said the same could be true for insulin-producing cells. "If the fly cells are using the same molecules and genes as humans, then there's a good chance that much of the pathway of development is conserved," he said.

To make the diabetic flies, Rulifson first identified a group of cells in the brain that produce insulin. He then specifically destroyed only those insulin-producing cells in the fly larvae. These larvae were significantly smaller than their normal counterparts and took longer to develop into full-fledged flies. What's more, the fly larvae that lacked insulin had high blood-sugar levels, comparable to human diabetes.

When Rulifson looked at where the insulin-producing cells were located in the fly brain, he found that they sent projections to the heart, where the nerves released insulin into the larvae's circulatory system. This is similar to how the pancreatic cells release insulin into the human bloodstream.

The nerves also sent projections to a group of cells that release a protein similar to human glucagon. This substance has the opposite effect of insulin - causing cells to release stored sugar into the blood when blood-sugar levels are low. Together, the two opposing hormones keep human blood-sugar levels steady, and may do the same in flies.

Rulifson called these similarities between fly and human hormonal systems "the tip of the iceberg." He said there is enough similarity to suspect his diabetic flies will be good models for the human disease. "This fly model could help us understand the origin of insulin-producing cells in people," he said.


'"/>

Contact: Amy Adams
amyadams@stanford.edu
650-723-3900
Stanford University Medical Center
9-May-2002


Page: 1 2

Related biology news :

1. Tiny molecules have big potential as cancer drugs, Stanford researcher believes
2. Stanford researchers findings may shed light on common, deadly birth defect
3. Leukemia stem cells identified by Stanford researchers
4. New view of leukemia cells identifies best treatment options, Stanford researchers say
5. Confidentiality of genetic databases questioned by Stanford researchers
6. Stanford researchers go from heaven to Earth in lifeguard test
7. Transplant rejection averted by simple light exposure in Stanford animal study
8. Fat cells heal skull defects in mice, Stanford research shows
9. Gene-based screen sorts cancer cases, say Stanford researchers
10. Elusive but ubiquitous microbe fingered as gum disease culprit in Stanford study
11. Sticklebacks reveal secrets to evolutionary change in Stanford study

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Stanford researchers create diabetic fruit flies lab

(Date:10/15/2014)... is a non-traditional biophysics textbook and it describes how ... journey of discovery into biological systems and provides an ... It is about how our genes make proteins that ... of cells in an organism. It quantifies the principles ... can be found on both large and small scales. ...
(Date:10/15/2014)... Alt will be awarded the 44th Rosenstiel Award for ... his pioneering research exploring the mechanisms of genomic instability ... cells. Alt is the second alumnus to win the ... Prize in 2003. , Alt is the Charles A. ... Harvard Medical School and an investigator at the Howard ...
(Date:10/14/2014)... N.Y. – Scientists have sequenced the house fly genome ... one might expect from an insect that thrives in ... published Oct. 14 in the journal Genome Biology ... biology and of how flies quickly adapt to resist ... Adult house flies (Musca domestica) carry and transmit more ...
Breaking Biology News(10 mins):New book about life as seen from physics 2Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2House fly genome reveals expanded immune system 2
(Date:10/22/2014)... , Oct. 22, 2014   Synthetic Biologics, ... novel pathogen-specific therapies for serious infections and diseases, announced ... issued a Notice of Allowance for a composition of ... C. difficile program, SYN-004. This is Synthetic ... in the U.S. and adds to the Company,s extensive ...
(Date:10/22/2014)... SAN DIEGO and HONG KONG ... an innovative rare disease therapeutics enterprise, announced today that ... joined the company as vice president, research. Dr. McKew ... research, including key leadership positions at the National Institutes ... to its acquisition by Wyeth). Dr. McKew will lead aTyr,s ...
(Date:10/20/2014)... 2014 Asterias Biotherapeutics, Inc. (NYSE MKT: ... a Notice of Grant Award (NGA) with the ... 1, 2014.  The NGA provides for the immediate ... of additional grant funds pursuant to the previously ... development of Asterias, product, AST-OPC1. The grant provides ...
(Date:10/20/2014)... , Oct. 20, 2014 PureTech ... company tackling big healthcare problems, announced today the ... round, with participation from Invesco Perpetual, a $120 ... used to drive PureTech,s existing pipeline forward and ... "PureTech has the scientific creativity to really go ...
Breaking Biology Technology:Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6
Cached News: